A61P 37 - Drugs for immunological or allergic disorders

Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
12/2004
12/14/2004	CA2225453C Compounds with chelation affinity and selectivity for first transition series elements, and their use in medical therapy and diagnosis
12/14/2004	CA2104957C Redirection of cellular immunity by receptor chimeras
12/09/2004	WO2004106384A1 Antibodies to masp-2
12/09/2004	WO2004106317A1 Benzofuran compound and medicinal composition containing the same
12/09/2004	WO2004106312A1 Novel 2-aminoselenazoline derivative and use thereof
12/09/2004	WO2004106305A1 New p2x7 receptor antagonists and their use
12/09/2004	WO2004105789A1 Grf analog compositions and their use
12/09/2004	WO2004105775A1 Pharmaceutical composition comprising glucan derived from microalgae
12/09/2004	WO2004105760A1 Use of efletirizine for treating persistent allergic rhinitis
12/09/2004	WO2004105759A2 Novel long-acting medicament combinations comprising an anticholinergic agent and a $g(b)2-adrenoreceptor antagonist for the treatment of respiratory tract diseases
12/09/2004	WO2004087699A3 Thiazoles useful as inhibitors of protein kinases
12/09/2004	WO2004087698A3 Thiazoles useful as inhibitors of protein kinases
12/09/2004	WO2004083249A3 Antibodies against human il-21 receptor and uses therefor
12/09/2004	WO2004078175A3 Pharmaceutical preparations containing thiazolidinediones for the treatment or prevention of ip-10 mediated diseases
12/09/2004	WO2004060262A3 Modulators of notch signalling for use in immunotherpapy
12/09/2004	WO2003097082A3 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
12/09/2004	WO2003080582A3 Fredericamycin derivatives
12/09/2004	WO2003072114A9 Vascular therapeutics
12/09/2004	WO2003053219A3 Methods for slowing senescence and treating and preventing diseases associated with senescence
12/09/2004	US20040249161 Biphenyl-derivatives as p38-kinase inhibitors
12/09/2004	US20040249159 Novel piperidin-2,6-dione disulphate salts and their use for the treatment of stress related affective disorders
12/09/2004	US20040249153 For therapy of inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors
12/09/2004	US20040249132 Nuclear hormone receptor ligand binding domain
12/09/2004	US20040249123 Nuclear receptor for use in identifying modulator for diagnosis, prevention and treatment of cell proliferative, blood, cardiovascular, skin, inflammatory, bone and nervous system disorders
12/09/2004	US20040248935 crystals, crystal structured, liquid crystals and/or amorphous forms of 4-[4[4-(hydroxy diphenyl methyl)-1-piperidenyl]-1-hydroxy butyl]- alpha , alpha -dimethylphenyl acetic acid, hydrochloride salts, used as antihistamines, antiallergens or bronchodilator agents
12/09/2004	US20040248923 Novel 4-anilinoquinoline-3-carboxamides
12/09/2004	US20040248920 Spiro-hydantoin compounds useful as anti-inflammatory agents
12/09/2004	US20040248908 Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
12/09/2004	US20040248889 Analgesics; synthesis
12/09/2004	US20040248886 Neuronal disorders, autoimmune diseases, cancer, cardiovascular diseases; such as 4-Chloro-N-{5-[1-(4-trifluoromethyl-benzyl)-piperidin-3-ylsulfamoyl]-25 thiophen-2-ylmethyl)-benzamide
12/09/2004	US20040248870 High-purity composition comprising (7alpha, 17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one and a process for purifying (7alpha, 17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
12/09/2004	US20040248867 Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
12/09/2004	US20040248820 Administering 2-phthalimidoglutaric acid; vision defects; antitumor agents; anticancer agents
12/09/2004	US20040248810 Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
12/09/2004	US20040248792 Thymosin alpha 1 peptide/.polymer conjugates
12/09/2004	US20040248787 fusion protein comprising a PTD (protein transduction domain) and an MITF (microphthalmia-associated transcripution factor) variant as an active ingredient with a His tag
12/09/2004	US20040248781 Therapeutic method for reducing angiogenesis
12/09/2004	US20040248772 yeast-derived ingredient having beta 1,3/1.6 glucan structure (IMMUTOL) or Norwegian Beta Glucan (TM); natural killer cell activating capabilities and tumor angiogenesis inhibiting capability by oral administration
12/09/2004	US20040248769 hydrolytic; inhibits arginyl endopeptidase or serine protease activity; air cleaner; fabric treatment
12/09/2004	US20040248767 Modulating serum amyloid a interaction with tanis and agents useful for same
12/09/2004	US20040248324 Fhm a novel member of the TNF ligand supergene family: materials and methods for interaction modulators
12/09/2004	US20040248321 Membrane protein for use in treatment and prevention of inflammatory, circulatory, cell proliferative, metabolic and immunological disorders
12/09/2004	US20040248252 Nucleotide sequences coding mammalian histamine H4 receptor protein for use in diagnosis, prevention and treatment of asthma, allergy, inflammation, thrombotic, cardiovascular and autoimmune disorders
12/09/2004	US20040248251 Receptors and membrane associated proteins
12/09/2004	US20040248249 Protein for use in treatment, prevention and diagnosis of cell proliferative, autoimmune/inflammatory, cardiovascular, neurological, and developmental disorders
12/09/2004	US20040248243 Lipid metabolizing polypeptide for use in identifying modulators for treatment and prevention of cancer, nervous system, autoimmune/inflammatory, gastrointestinal and cardiovascular disorders
12/09/2004	US20040248208 Screening method
12/09/2004	US20040248192 Composition
12/09/2004	US20040248188 Methods for using tetanus toxin for benificial purposes in animals (mammals)
12/09/2004	US20040248173 Nucleotide sequences coding cyclic peptide receptor for use in identifying modulators for treatment of pituitary hormone, epinephrine release, gastrointestinal, cardiovascular, electrolyte balance, hypertensive, diabetic and respiratory system disorder
12/09/2004	US20040248124 Nucleic acid encoding polypeptide involved in cellular entrance of the prrs virus
12/09/2004	US20040247712 administering a food, chewing gum or drink containing a treated product of peanut seed coats, to a patient suffering from allergies
12/09/2004	US20040247662 Systemic immune activation method using nucleic acid-lipid complexes
12/09/2004	US20040247658 Delivery system with increased bioavailability
12/09/2004	US20040247643 A miniature coated tablet or covered rod implant; smaller size and larger payloads than immediate release tablets; veterinary medicine
12/09/2004	US20040247598 In particular of delayed-type hypersensitivity; especially administering an IL-18 binding protein or a derivative, an expression vector or a genetically engineered cell, optionally with an antiinflammatory agent such as a COX-inhibitor.
12/09/2004	US20040247592 Administering a substance that modulates an ephrin or an Eph receptor, especially treating cancer by modulating an adhesive, migratory or chemotactic property of a cancer cell; also treating autoimmune diseases, allergies, graft versus host disease, and transplant rejection
12/09/2004	US20040247581 Bacterial strains that adhere to intestinal gut (capability to adhere to the cell lines Caco-2 or Hep-2) and lowering the concentration of pathogenic peptides (measured as peptidase activity), used to treat behavioral or psychiatric disorders, such as autism, ADHD, mood disorders, and schizophrenia
12/09/2004	CA2527178A1 New long-acting drug combinations for the treatment of respiratory complaints
12/09/2004	CA2527039A1 Grf analog compositions and their use
12/09/2004	CA2519835A1 Method of treating corneal transplant rejection
12/08/2004	EP1484402A2 Antibody for use in therapy
12/08/2004	EP1484397A1 Peptide from antigen MUC-1 for triggering an immune response to tumor cells
12/08/2004	EP1484064A1 Therapeutical composition containing dentritic cells and use thereof
12/08/2004	EP1484063A2 Method for inhibiting rejection of transplanted tissue
12/08/2004	EP1484061A1 Drugs containing riboflavin-type compounds
12/08/2004	EP1484055A1 Delivery system with increased bioavailability
12/08/2004	EP1484054A1 Drug delivery system for the subconjunctival administration of fine grains
12/08/2004	EP1483384A2 Method for overexpression of zwitterionic polysaccharides
12/08/2004	EP1483374A2 Use of l-alpha-lysophosphatidycholine to obtain the differentiation of monocytes in mature dendritric cells in vivo
12/08/2004	EP1483289A2 Angiogenesis regulator genes, pharmaceutical preparations containing same and uses thereof
12/08/2004	EP1483261A1 Phthalimide carboxylic acid derivatives
12/08/2004	EP1483260A1 Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament
12/08/2004	EP1483244A1 Cyclic n-substituted alpha iminocarboxylic acids for selectively inhibiting collagenase
12/08/2004	EP1483242A1 Nitrosodiphenylamine derivatives and their pharmaceutical use against oxidative stress pathologies
12/08/2004	EP1482984A2 Surrogate antibodies and methods of preparation and use thereof
12/08/2004	EP1482983A2 Non-myeloablative tolerogenic treatment with tyrphostins
12/08/2004	EP1482974A2 Electroporation methods for introducing bioactive agents into cells
12/08/2004	EP1482973A1 Methods of modulating cd200 receptors
12/08/2004	EP1482972A2 Treatment of immunological disorders using anti-cd30 antibodies
12/08/2004	EP1482962A2 Method of treating trx mediated diseases
12/08/2004	EP1482961A2 Use of soluble fgl2 as an immunosuppressant
12/08/2004	EP1482959A1 Compositions and methods for treatment of skin disorders
12/08/2004	EP1482955A1 Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
12/08/2004	EP1482951A1 Alpha-hydroxy-2-methylene-10-nor-pregnacalciferol and its uses
12/08/2004	EP1482941A1 Beta-sheet mimetics and composition and methods relating thereto
12/08/2004	EP1482938A1 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
12/08/2004	EP1482937A2 Novel tyloindicines and related processes, pharmaceutical compositions and methods
12/08/2004	EP1482933A2 Potent, simplified derivatives of immunosuppressive agents
12/08/2004	EP1482926A2 Amino-methyl substituted tetracycline compounds
12/08/2004	EP1482911A1 Dispersed solid-containing complex carbohydrate
12/08/2004	EP1482896A2 Aminoalkylphosphonates and related compounds as edg receptor agonists
12/08/2004	EP1482895A2 Aminoalkylphosphonates and related compounds as edg receptor agonists
12/08/2004	EP1482811A1 Probiotic delivery system
12/08/2004	EP1482795A1 New immunoeffector compounds
12/08/2004	EP1482787A2 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
12/08/2004	EP1363898A4 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
12/08/2004	EP1341754B1 Substituted anthranilic acids
12/08/2004	EP1326960B1 Microbes having an attenuating mutation comprising a transcription terminator
12/08/2004	EP1303290A4 Small peptides and methods for downregulation of ige

1 ... 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 ... 1172